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Background: Acute gastroenteritis (AGE) is a major reason for presentation to pediatric primary emergency medical
centers. Because rotavirus vaccines were introduced in November 2011 for voluntary vaccination in Japan, we
analyzed the changes in the numbers of AGE patients.
Methods: The number and proportion of patients visiting Kobe children’s primary emergency medical center from
January 2011 to February 2015 due to AGE, out of all visiting children, were investigated retrospectively. The
rotavirus and norovirus epidemic periods were defined as the periods from March to June and from November to
February, respectively, based on their disease prevalence.
Results: In patients ≤2 years of age, the numbers and proportions of patients with AGE were significantly
decreased from 2464/14098 (17%) in 2011 to 1888/12321 (15%) in 2014 (p < 0.01). In patients ≤2 and 3–5 years
of age, significant decreases in AGE patients between 2011 and 2014 were observed during the rotavirus
season (from 20% [1090/5329] to 14% [642/4482] in patients aged ≤2 years and from 23% [704/3047] to 20%
[572/2807] in patients aged 3–5 years, p < 0.01 and p < 0.05, respectively), but not during the norovirus season
(from 19% [834/4436] to 19% [797/4160] in patients aged ≤2 years and from 20% [679/3334] to 25% [710/2852]
in patients aged 3–5 years).
Conclusions: The estimated rotavirus vaccine coverage in our area increased from 1% in 2011 to 49% in 2014;
this coverage may have resulted in a reduction in AGE patients, both directly and indirectly, in our Japanese
children’s primary emergency medical center.
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Worldwide, rotavirus is a common causative virus of
acute gastroenteritis (AGE) in children [1], and, in 2008,
approximately 453,000 rotavirus AGE-related deaths oc-
curred in children younger than 5 years of age [2]. Al-
though death is relatively rare in Japan, AGE due to
rotavirus represents a heavy disease burden for providing
medical treatment not only in hospitals, but also in
pediatric outpatient clinics [3–5]. In Japan, approxi-
mately 26,000–78,000 hospitalizations and 800,000 visits
to outpatient clinics or outpatient department of hospi-
tals due to rotavirus AGE have been estimated annually
in children under school age [3–5]. From many coun-
tries where the rotavirus vaccine has already been intro-
duced, the direct effects thereof have been reported,
including reduced numbers of pediatric AGE patients re-
quiring hospitalization, outpatient visits, and emergency
department visits [6–14].
A live attenuated monovalent human rotavirus vac-
cine (Rotarix™: GlaxoSmithKline Biologicals, Rixensart,
Belgium) and a pentavalent human-bovine reassortant
rotavirus vaccine (RotaTeq™: Merck & Co., Inc., New
Jerzy, USA) were introduced for voluntary vaccination
in Japan in November 2011 and July 2012, respectively.
Rotarix™ is derived from the single-strain human rota-
virus with G1P[8] genotype and RotaTeq™ includes 5
bovine-human recombinant rotaviruses with genotypes
of G1P[5], G2P[5], G3P[5], G4P[5], and G6P[8]. An
early study showed reduced rates of severe pediatric
AGE due to rotavirus after the introduction of volun-
tary rotavirus vaccination at 3 pediatric outpatient
clinics in Shibata-city, Niigata prefecture, Japan [15, 16].
However, the direct and indirect effects of this vaccine
have not yet been studied in a children’s primary emer-
gency medical center, which is a unique Japanese medical
service system.
Kobe children’s primary emergency medical center
provides medical services for pediatric patients with-
out trauma, only during holidays and outside of regu-
lar working hours. Approximately 30,000 pediatric
patients per year visit this center, which covers 50–
60% of all primary emergency patients in Kobe-city
(52% in 2011, 57% in 2012, 59% in 2013, and 58% in
2014). More than 130 pediatricians are working on a
part-time basis.
The purpose of this study was to analyze the
changes in the numbers and proportions of patients
with AGE and severe AGE after the voluntary-based
introduction of rotavirus vaccines in Kobe children’s
primary emergency medical center. Moreover, we also
investigated if there were any changes in the numbers
and proportions of AGE and severe AGE patients
specifically during the rotavirus and norovirus epi-
demic seasons.Methods
Subjects and analysis
All patients ≤ 15 years of age who visited Kobe children’s
primary emergency medical center from January 1, 2011
to February 28, 2015 were enrolled in this retrospective
study. No exclusion criteria were established. Patients
were classified into three subgroups based on age; ≤ 2,
3–5, and ≥ 6 years of age. The AGE patients were identi-
fied from the medical database based on the diagnosis of
AGE, and the numbers of AGE patients in the full sea-
son, rotavirus season, and norovirus season were calcu-
lated from 2011 to 2014. The proportions of AGE and
severe AGE patients in each season were calculated
based on the number of total patients who visited our
center. In patients ≤ 2 years of age, the numbers and
proportions for each season in 2012, 2013, and 2014
were compared with those in 2011, when the rotavirus
vaccines were just introduced in Japan, which served as
the baseline. Patients with 3 to 5 years of age, or ≥ 6 years
of age were also analyzed for investigating indirect ef-
fects of vaccination. In the examined stools of AGE pa-
tients, the detection numbers and rates of rotavirus
during the rotavirus season from 2011 to 2014 were ana-
lyzed. Finally, from the medical database, the number of
patients < 12 months of age with a confirmed diagnosis
of intussusception were calculated for each year, because
intussusception is a major side effect of the rotavirus
vaccine [17–19].
The study design and data collection for this study
were approved by the Ethical Committee of Kobe
Children’s Primary Emergency Medical Center (no. 57-4;
approved on November 7, 2014). All procedures per-
formed in studies involving human participants were in
accordance with the ethical standards of the institutional
and national research committee and with the 1964
Helsinki declaration and its later amendments or com-
parable ethical standards. For this type of study formal
consent is not required.
Definitions
The diagnosis of AGE was made at the discretion of the
attending pediatrician based on the clinical manifesta-
tions, such as vomiting, diarrhea, fever, and abdominal
pain, and only some patients were confirmed to have the
causative virus in their stool using an antigen detection
kit. AGE patients who required intravenous infusion
and/or hospitalization were defined as “severe”. “Full
season” was defined as the period between January and
December each year. The two major causative viruses
for AGE are rotavirus and norovirus [13, 20]. Currently,
a norovirus vaccine is not commercially available. The
“rotavirus season” was defined as the rotavirus epidemic
period between March and June, and the “norovirus
season” as the norovirus epidemic period between
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lence in Japan [21].
Estimated vaccine coverage in Hyogo prefecture
The estimated vaccine coverage in Hyogo prefecture was
calculated using the following formula: (estimated vac-
cine coverage, %) = 100 × [(shipping number of Rotarix™/
2 in a year) + (shipping number of RotaTeq™/3 in a
year)]/(the birth number in a year), because Rotarix™ is
inoculated 2 times before 6 months of age and RotaTeq™
is inoculated 3 times before 8 months of age for infants.
The data of the shipping number in Hyogo prefecture
were obtained from the pharmaceutical companies of
the rotavirus vaccines.
Statistical analysis
Data are presented as the number (percentage). Chi-
square tests were performed using Excel Statistics
(Statcel 3; Social Survey Research Information Co. Ltd.,
Tokyo, Japan). For all analyses, p < 0.05 was considered
statistically significant.
Results
Total and AGE patients during the study period
A total of 125,968 patients ≤ 15 years of age visited Kobe
children’s primary emergency medical center from
January 1, 2011 to February 28, 2015. The total numbers
of patients ≤ 2, 3–5, and ≥ 6 years of age were 56,641,
34,419, and 34,908, respectively. The total number of
AGE patients was 23,615 and the proportion of AGE pa-
tients of the total number of patients was 18.7%. The
monthly trends of AGE patients in our center fromFig. 1 Monthly numbers of AGE patients≤ 15 years of age from January 1,
epidemic seasons. Dotted squares indicate rotavirus epidemic seasons. AGEJanuary 2011 to February 2015 are shown in Fig. 1. For
each year, the epidemic of AGE showed a binomial dis-
tribution in spring and winter.
Patients ≤ 2 years of age
In the full season, a total of 14,098, 14,112, 13,826, and
12,321 patients ≤ 2 years of age visited the center in 2011,
2012, 2013, and 2014, respectively. The numbers and pro-
portions of AGE and severe AGE patients ≤ 2 years of age
in the full season each year are shown in Fig. 2. The pro-
portion of AGE patients was significantly decreased from
17.4% in 2011 to 15.3% in 2014 (p < 0.01), but not in 2012
(20.3%) or 2013 (16.9%). The proportion of severe AGE
patients was significantly decreased from 2.9% in 2011 to
2.2% in 2013 and 1.6% in 2014 (p < 0.01), whereas no dif-
ference was seen in 2012 (3.0%).
The annual trends of the numbers and proportions of
AGE and severe AGE patients in the rotavirus season
and norovirus season are shown in Figs. 3 and 4. The
proportion of AGE patients was significantly decreased
from 20.4% in 2011 to 14.3% in 2014 in the rotavirus
season (p < 0.01). However, no significant decrease was
found from 2011 to 2014 in the norovirus season. The
proportion of severe AGE patients was also significantly
decreased from 4.3% in 2011 to 3.2% in 2013 and 1.7%
in 2014 in the rotavirus season (p < 0.01), whereas there
was no significant decrease in the norovirus season.
Patients 3–5 years of age
The numbers and proportions of AGE and severe AGE
patients aged 3–5 years are shown in Table 1. The propor-
tion of severe AGE patients was significantly decreased2011 to February 28, 2015. Black squares indicate the norovirus
, acute gastroenteritis
Fig. 2 Numbers and proportions of a AGE and b severe AGE patients≤ 2 years of age. Gray columns indicate the numbers of AGE or severe AGE
patients≤ 2 years of age in the full season each year. The line indicates the proportions of AGE or severe AGE patients based on the total number
of visiting patients. ** p < 0.01 compared with in 2011. AGE, acute gastroenteritis
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decrease was found in the proportions of AGE patients
(19.8% in 2011 and 21.1% in 2014). In the rotavirus
season, the proportions of AGE and severe AGE pa-
tients were significantly decreased from 23.1% and 5.2% in
2011 to 20.4% and 3.2% in 2014 (p < 0.05 and p < 0.01,
respectively). On the other hand, in the norovirus season,
no significant decrease in the proportions of AGE and se-
vere AGE patients was found between 2011 and 2014.
Patients ≥ 6 years of age
The numbers and proportions of AGE and severe AGE
patients ≥ 6 years of age are shown in Table 2. No
change was observed in the proportion of AGE patientsFig. 3 Numbers and proportions of AGE patients≤ 2 years of age in the a
stripe columns indicate the numbers of AGE patients≤ 2 years of age in the
indicates the proportions of AGE patients based on the total numbers of visitbetween 2011 and 2014. A significant decrease in the
rotavirus season was found between 2011 and 2012 but
not between 2011 and 2014.
Detection number and rate of rotavirus
Detection numbers and rates of rotavirus in AGE pa-
tients during the rotavirus season from 2011 to 2014
were shown in Table 3. In the examined stools of AGE
patients, the detection rate was significantly decreased
from 67% in 2011 to 27% in 2014 (p < 0.01).
Number of intussusceptions
The numbers of patients < 12 months of age with a con-
firmed diagnosis of intussusception were 2, 3, 3, and 4 inrotavirus and b norovirus epidemic seasons. Gray columns and gray
rotavirus season and norovirus season each year, respectively. The line
ing patients. ** p < 0.01 compared with in 2011. AGE, acute gastroenteritis
Fig. 4 Numbers and proportions of severe AGE patients≤ 2 years of age in the a rotavirus and b norovirus epidemic seasons. Gray columns and
gray stripe columns indicate number of severe AGE patients≤ 2 years of age in the rotavirus season and norovirus season each year, respectively.
The line indicates the proportions of severe AGE patients based on the total number of visiting patients. ** p < 0.01 compared with in 2011. AGE,
acute gastroenteritis
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istical difference during the study period (p = 0.79).
Estimated vaccine coverage in Hyogo prefecture
The estimated vaccine coverage rates in Hyogo prefec-
ture were 1% in 2011, 25% in 2012, 42% in 2013, and
49% in 2014.
Discussion
In Japan, the rotavirus vaccine was first introduced in
November 2011 on a voluntary basis. Herein, we ana-
lyzed the changes in the numbers and proportions of pa-
tients with AGE and severe AGE after the voluntary-
based introduction of rotavirus vaccines in Kobe chil-
dren’s primary emergency medical center. As results, in
patients ≤ 2 and 3–5 years of age, the proportions of
AGE and severe AGE patients based on the total num-
ber of patients who visited our center were significantly
decreased between 2011 and 2014 in the rotavirus sea-
son, but not in the norovirus season. In patients ≥ 6 years
of age, the years in which we observed a significant de-
crease of the proportions of severe AGE patients com-
pared to in 2011 did not correspond between the fullTable 1 Numbers and proportions of AGE and severe AGE patients
Full season Rotav
2011 2012 2013 2014 2011
Total number of patients 8484 8510 7992 7781 3047
AGE patients 1681 (20) 1974 (23) 1735 (22) 1647 (21) 704 (
Severe AGE patients 331 (4) 343 (4) 293 (4) 247 (3)* 159 (
Data are presented as n (%). AGE, acute gastroenteritis
*p < 0.05 and **p < 0.01 compared with in 2011season and rotavirus season. The rotavirus vaccine
coverage in our area increased to 49% in 2014. This
coverage may have resulted in a reduction in the num-
bers of patients ≤ 2 and 3–5 years of age presenting with
AGE and severe AGE in the rotavirus season in our Jap-
anese primary emergency medical center.
Rotavirus vaccine is inoculated to infants < 6 months
of age for Rotarix™ or < 8 months of age for RotaTeq™.
Therefore, the reductions in AGE and severe AGE pa-
tients ≤ 2 years of age in the rotavirus season might rep-
resent direct effects of vaccination. In patients ≤ 2 years
of age, severe AGE and AGE were significantly de-
creased in 2013 and 2014, and 2014, respectively, as
compared in 2011. Oishi et al. reported a significant re-
duction of severe rotavirus AGE 1 year after the vaccine
introduction (estimated vaccine coverage, 33%) [15].
Another reason of the reduction of AGE patients may
be the increase in preventive measures such as improved
hand hygiene and environmental disinfection during the
study period. And the reduction of severe AGE patients
may associate with the increase in use of oral rehydra-
tion solution at home. However, because there was no
reduction in the proportion of AGE and severe AGEaged 3 to 5 years
irus season Norovirus season
2012 2013 2014 2011 2012 2013 2014
2771 2625 2807 3334 3089 3093 2852
23) 696 (25) 643 (24) 572 (20)* 679 (20) 782 (25) 760 (25) 710 (25)
5) 135 (5) 128 (5) 89 (3)** 129 (4) 121 (4) 114 (4) 124 (4)
Table 2 Numbers and proportions of AGE and severe AGE patients aged ≥ 6 years
Full season Rotavirus season Norovirus season
2011 2012 2013 2014 2011 2012 2013 2014 2011 2012 2013 2014
Total number of patients 8306 8669 7522 7941 2775 2816 2399 2591 4036 3333 3527 3765
AGE patients 1730 (21) 1830 (21) 1758 (23) 1706 (21) 634 (23) 552 (20)** 588 (25) 577 (22) 740 (18) 900 (27) 771 (22) 753 (20)
Severe AGE patients 407 (5) 385 (4) 329 (4) 332 (4)* 161 (6) 112 (4)** 132 (6) 123 (5) 169 (4) 190 (6) 147 (4) 165 (4)
Data are presented as n (%). AGE, acute gastroenteritis
*p < 0.05 and **p < 0.01 compared with in 2011
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not major reasons for the reduction of AGE and severe
AGE patients.
Because our study calculated the proportion of AGE
or severe AGE patients based on the total number of
visiting patients, the data may be influenced by epi-
demics of other viruses such as influenza. The epi-
demic season of influenza is usually the same as that
of norovirus in Japan. Although, during the study
period, the highest number of influenza patients vis-
ited our center in 2012 (data not shown), no decrease
in the percentage of AGE or severe AGE was found
in 2012 during the full and norovirus seasons, indi-
cating that there was likely no major influence of in-
fluenza on the results.
Some previous studies have shown decreased rates of
AGE and severe AGE after the rotavirus vaccine intro-
duction for infants in adults and older children as well
(indirect effects of vaccine) [14, 22, 23]. In the present
study, patients older than 3 years of age during the study
period were not administered the rotavirus vaccine
(except for a small number of patients aged 3 years in
2014 who were inoculated with Rotarix™ in 2011). Our
results thus suggest that indirect effects of the rotavirus
vaccine appeared in children aged 3–5 years, but not in
children ≥ 6 years of age. Although the detailed reasons
of this discrepancy are not clear, the vaccine coverage
might still be too low to show indirect effects for chil-
dren ≥ 6 years of age.
Finally, intussusception is a major side effect of the
rotavirus vaccine, especially within 7 days after the first
inoculation [18, 19]. Therefore, we investigated the num-
ber of cases of intussusception in infant patients. In our
center, there was no increase in the number of patientsTable 3 Detection numbers and rates of rotavirus in AGE
patients during the rotavirus season
2011 2012 2013 2014
Examined stools of AGE patients, n 84 96 79 30
Positive result of rotavirus, n 56 55 47 8
Detection rate, % 66.7 57.3 59.5 26.7**
AGE, acute gastroenteritis
**p < 0.01 compared with in 2011with intussusception over time, even as the vaccine
coverage increased.
This study has some limitations: 1) the causative virus
was not always determined from stool samples of the
AGE patients, because this study was conducted in a pri-
mary emergency medical center where we provide only
primary medical care or screening of patients with se-
vere conditions requiring hospitalization. We cannot ac-
curately determine if the reduction of AGE patients was
due to the reduction of rotavirus AGE patients. Al-
though the limited AGE patients were examined and the
number of examined stools varied each year, the detec-
tion rate of rotavirus in 2014 significantly decreased as
compared with that in 2011. The trends of AGE patients
caused by rotavirus in our center corresponded with the
national epidemiological data [21]. To make up for this
major limitation, we classified the study period into 2
seasons based on the prevalence of rotavirus infections
in Japan [21]: the “rotavirus season” and “norovirus
season,” and clearly showed the reduction of AGE pa-
tients only in the rotavirus season. 2) The criteria of se-
vere AGE were not uniform, owing to the fact that the
study was conducted at a large primary emergency med-
ical center where more than 130 pediatricians are work-
ing on a part-time basis. 3) The rotavirus vaccine
inoculation rate in patients who developed AGE and se-
vere AGE was not known. If we can obtain this data, the
vaccine effects may be assessed accurately. 4) This study
used the patient number in 2011 as a reference. The
ideal reference period should be included the years be-
fore the rotavirus vaccine introduction, such as 2009 to
2011. However, because our children’s primary emer-
gency medical center was opened in December, 2010, we
could not expand the reference period. Despite these
limitations, this study, for the first time, clearly showed
the changes in the numbers and proportions of patients
with AGE after the voluntary introduction of the rota-
virus vaccine in a Japanese children’s primary emergency
medical center.
Conclusions
The numbers and proportions of AGE and severe AGE
patients not only aged ≤ 2 years, but also 3–5 years, de-
creased in the rotavirus season 3 years after the
Morioka et al. Environmental Health and Preventive Medicine  (2017) 22:15 Page 7 of 7voluntary introduction of the rotavirus vaccine in a
Japanese children’s primary emergency medical center.
Although the epidemic trends of AGE vary each year,
the rotavirus vaccine may lead to a decreased AGE bur-




We thank Ms. Y. Hanabata for secretarial assistance.
Funding
A Grant for Scientific Research (C) of JSPS KAKENHI (Grant Number: JP26461632,
I.M.) supported the English language editing in this manuscript.
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
IM, AI and KIi designed the study; IM and NK performed the statistical
analysis and drafted the manuscript; IM, NK, MN, TY, SM, SI, HN, KN, NN, MT-I
and KIs collected and analyzed data; MN, TY, SM, SI, HN, KN, NN, MT-I, KIs, AI
and KIi critically reviewed the manuscript. All authors read and approved the
final manuscript.
Competing interest
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study design and data collection for this study were approved by the
Ethical Committee of Kobe Children’s Primary Emergency Medical Center
(no. 57–4; approved on November 7, 2014). All procedures performed in
studies involving human participants were in accordance with the ethical
standards of the institutional and national research committee and with the
1964 Helsinki declaration and its later amendments or comparable ethical
standards. For this type of study formal consent is not required.
Author details
1Department of Pediatrics, Kobe University Graduate School of Medicine,
7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. 2Kobe Children’s
Primary Emergency Medical Center, Kobe 6510073, Japan.
Received: 17 November 2016 Accepted: 13 January 2017
References
1. Kapikian AZ. Overview of viral gastroenteritis. Arch Virol Suppl. 1996;12:7–19.
2. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al.
2008 estimate of worldwide rotavirus-associated mortality in children
younger than 5 years before the introduction of universal rotavirus
vaccination programmes: a systematic review and meta-analysis. Lancet
Infect Dis. 2012;12:136–41.
3. Yokoo M, Arisawa K, Nakagomi O. Estimation of annual incidence, age-
specific incidence rate, and cumulative risk of rotavirus gastroenteritis
among children in Japan. Jpn J Infect Dis. 2004;57:166–71.
4. Nakagomi T, Nakagomi O, Takahashi Y, Enoki M, Suzuki T, Kilgore PE. Incidence
and burden of rotavirus gastroenteritis in Japan, as estimated from a
prospective sentinel hospital study. J Infect Dis. 2005;192 Suppl 1:S106–10.
5. Kinoshita S, Noguchi A, Miura S, Nakagomi T, Nakagomi O, Takahashi T. A
retrospective, hospital-based study to determine the incidence of rotavirus
hospitalizations among children less than 5 years of age over a 10-year
period (2001–2011) in Akita prefecture, Japan. Jpn J Infect Dis. 2014;67:464–8.
6. Braeckman T, Van Herck K, Meyer N, Pircon JY, Soriano-Gabarro M, Heylen E,
et al. Effectiveness of rotavirus vaccination in prevention of hospital
admissions for rotavirus gastroenteritis among young children in Belgium:
case-control study. BMJ. 2012;345:e4752.7. Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ, et al.
Effectiveness of pentavalent and monovalent rotavirus vaccines in
concurrent use among US children <5 years of age, 2009–2011. Clin Infect
Dis. 2013;57:13–20.
8. Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP, et al.
Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics.
2013;132:e25–33.
9. Hartwig S, Uhari M, Renko M, Bertet P, Hemming M, Vesikari T. Hospital bed
occupancy for rotavirus and all cause acute gastroenteritis in two Finnish
hospitals before and after the implementation of the national rotavirus
vaccination program with RotaTeq. BMC Health Serv Res. 2014;14:632.
10. Hungerford D, Read JM, Cooke RP, Vivancos R, Iturriza-Gomara M, Allen DJ,
et al. Early impact of rotavirus vaccination in a large paediatric hospital in
the UK. J Hosp Infect. 2016;93:117–20.
11. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world
impact of rotavirus vaccination. Pediatr Infect Dis J. 2011;30:S1–5.
12. Chang WC, Yen C, Wu FT, Huang YC, Lin JS, Huang FC, et al. Effectiveness of
2 rotavirus vaccines against rotavirus disease in Taiwanese infants. Pediatr
Infect Dis J. 2014;33:e81–6.
13. Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, et al.
Norovirus and medically attended gastroenteritis in U.S. children. N Engl J
Med. 2013;368:1121–30.
14. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al.
Direct and indirect effects of rotavirus vaccination upon childhood
hospitalizations in 3 US Counties, 2006–2009. Clin Infect Dis. 2011;53:245–53.
15. Oishi T, Taguchi T, Nakano T, Sudo S, Kuwajima H. The occurrence of severe
rotavirus gastroenteritis in children under 3 years of age before and after
the introduction of rotavirus vaccine: a prospective observational study in
three pediatric clinics in Shibata City, Niigata Prefecture, Japan. Jpn J Infect
Dis. 2014;67:304–6.
16. Oishi T, Tsukano S, Nakano T, Sudo S, Kuwajima H. Impact of rotavirus
vaccination in severe rotavirus gastroenteritis outpatient visits at three
pediatric primary care clinics in Shibata city, Niigata prefecture, Japan. Open
Journal of Pediatrics. 2014;4:291–9.
17. Yung CF, Chong CY, Thoon KC. Age at first rotavirus vaccination and risk of
intussusception in infants: a public health modeling analysis. Drug Saf.
2016;39:745–8.
18. Bauchau V, Van Holle L, Mahaux O, Holl K, Sugiyama K, Buyse H. Post-
marketing monitoring of intussusception after rotavirus vaccination in
Japan. Pharmacoepidemiol Drug Saf. 2015;24:765–70.
19. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, et al.
Intussusception risk and disease prevention associated with rotavirus vaccines
in Australia’s National Immunization Program. Clin Infect Dis. 2013;57:1427–34.
20. Bartsch SM, Lopman BA, Ozawa S, Hall AJ, Lee BY. Global economic burden
of norovirus gastroenteritis. PLoS One. 2016;11, e0151219.
21. National Institute of Infectious Diseases. http://www.nih.go.jp/niid/images/
iasr/35/413/graph/f4131j.gif 2016. In Japanese
22. Anderson EJ, Shippee DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S,
et al. Indirect protection of adults from rotavirus by pediatric rotavirus
vaccination. Clin Infect Dis. 2013;56:755–60.
23. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may
provide indirect protection to older children and adults in the United
States. J Infect Dis. 2011;204:980–6.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
